Pfizer Inc. said on Thursday it would buy privately-held ReViral Ltd. in a deal worth as much as $525 million including milestone payments, to gain access to experimental drugs against the respiratory syncytial virus (RSV). The deal marks the U.S. drugmaker’s second acquisition in less than six months to boost its drug portfolio, after a…